Regadenoson
Top View
- Reversible Blood-Brain Barrier Opening Utilizing the Membrane Active Peptide Melittin in Vitro and in Vivo
- (12) Patent Application Publication (10) Pub. No.: US 2013/0224110 A1 Bynoe (43) Pub
- Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in Vivo by Decreasing of Fibrinogen Density in Thrombus
- Advances in Pharmacologic Stress Agents: Focus on Regadenoson
- Administration of Medicinal Products By
- 2019 Table of Drugs
- DEUTSCHE GESELLSCHAFT FÜR NUKLEARMEDIZIN E.V. DGN-Handlungsempfehlung (S1-Leitlinie) Myokard-Perfusions-SPECT Stand: 2/2017 –
- Brand Generic Guide
- The Effect of an Adenosine A2A Agonist on Intra-Tumoral
- Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
- Aminophylline Shortage and Current Recommendations for Reversal of Vasodilator Stress: an ASNC Information Statement Endorsed By
- Atc Index 2010
- The Academic News
- ORIGINAL ARTICLE Safety and Tolerability of Intravenous
- Lexiscan Patient Guide
- YOUR GUIDE to CONTINUING Heart and Vascular Care at Asante Rogue Regional Medical Center Welcome | 1
- Amplitude Integrated Electroencephalogram Study of the Effect of Caffeine Citrate on Brain Development in Low Weight Infants with Apnea
- Journal of Nuclear Cardiology